论文信息 - Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment - 字舞流文

Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment

F. Baldanti | P. Pedrazzoli | R. Schiavo | E. Percivalle | A. Sarasini | J. Sammartino | G. Lo Cascio | I. Cassaniti | G. Comolli | A. Lasagna | F. Bergami | A. Ferrari | D. Lilleri | M. Quaccini | F. Arena | D. Cicognini

[1] K. See. Vaccination for the Prevention of Infection among Immunocompromised Patients: A Concise Review of Recent Systematic Reviews , 2022, Vaccines.

[2] F. Baldanti,et al. Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study , 2022, ESMO Open.

[3] K. Pradhan,et al. Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer , 2021, Cancer Cell.

[4] F. Baldanti,et al. A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study , 2021, ESMO Open.

[5] B. Waissengrin,et al. Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors , 2021, The Lancet Oncology.